Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic
Immuneering | 8-K: Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic
Immuneering | 8-K:Immuneering公布2024年第三季度财务业绩并提供最新业务——公布了积极的初步数据,包括完全和部分反应,IMM-1-104与一线胰腺癌患者联合化疗-